(Total Views: 845)
Posted On: 03/24/2022 8:04:06 PM
Post# of 72445
Brilacidin Activ trial, somewhat hopeful.
Hey, this one failed primary endpoint on Phase 2B data, but still going to an advanced stage 3 as part of govt Activ trial.
Shionogi’s NIH-backed COVID-19 treatment is advancing to late-stage testing after the FDA finalized the drug’s study design. The trial is part of the National Institutes of Health’s ACTIV-2 study, which has been exploring multiple potential COVID outpatient therapies since late 2020. So far, data on Shionogi’s treatment has been mixed : Interim phase 2a results found that the therapy, dubbed S-217622, significantly reduced viral load, but phase 2b data found no major change in clinical symptoms, chalking up a failure on the primary endpoint . Story
https://www.fiercepharma.com/pharma/covid-tra...-antiviral
Hey, this one failed primary endpoint on Phase 2B data, but still going to an advanced stage 3 as part of govt Activ trial.
Shionogi’s NIH-backed COVID-19 treatment is advancing to late-stage testing after the FDA finalized the drug’s study design. The trial is part of the National Institutes of Health’s ACTIV-2 study, which has been exploring multiple potential COVID outpatient therapies since late 2020. So far, data on Shionogi’s treatment has been mixed : Interim phase 2a results found that the therapy, dubbed S-217622, significantly reduced viral load, but phase 2b data found no major change in clinical symptoms, chalking up a failure on the primary endpoint . Story
https://www.fiercepharma.com/pharma/covid-tra...-antiviral
(2)
(0)
